You are here

Clinical Trials: Cord Blood

Comment

Discuss
Body: Conditions:   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: Fludarabine;   Drug: mycophenolate mofetil;   Radiation: total marrow irradiation;   Procedure: umbilical cord blood transplantation;   Biological: Granulocyte colony-stimulating factor;   Biological: HLA-matched related donor bone marrow
Sponsor:   Masonic Cancer Center, University of Minnesota
Completed - verified July 2017
Body: Conditions:   Hurler's Syndrome;   Maroteaux-Lamy Syndrome;   Sly Syndrome;   Alpha Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Sphingolipidoses;   Krabbe Disease;   Wolman's Disease;   Niemann-Pick Disease Type B;   Niemann-Pick Disease, Type C
Interventions:   Procedure: Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Campath-1H;   Drug: Busulfan
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Body: Condition:   Osteopetrosis
Interventions:   Procedure: Stem Cell or Umbilical Cord Blood Transplantation;   Drug: Campath, Busulfan, Clofarabine;   Procedure: Total Lymphoid Irradiation
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Body: Condition:   Fanconi Anemia
Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Stem Cell Transplantation;   Drug: Methylprednisolone;   Drug: Filgrastim;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2017
Body: Condition:   Histiocytosis, Langerhans-cell
Interventions:   Biological: alemtuzumab;   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: stem cell transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Body: Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting
Body: Condition:   Leukemia
Interventions:   Drug: cyclosporine;   Drug: cytarabine;   Drug: filgrastim;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: mitoxantrone hydrochloride;   Procedure: allogeneic bone marrow transplantation;   Procedure: umbilical cord blood transplantation;   Drug: Cis-Retinoic acid
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Body: Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: umbilical cord blood transplantation;   Drug: Allopurinol;   Drug: fludarabine phosphate;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Biological: Treg infusion;   Drug: Sirolimus
Sponsor:   Masonic Cancer Center, University of Minnesota
Completed
Body: Conditions:   Myelodysplastic Syndrome (MDS);   Severe Aplastic Anemia (SAA)
Interventions:   Other: Umbilical Cord Blood;   Other: Haploidentical Stem Cells;   Device: Miltenvi CliniMACs CD34 Reagent System
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 6, 2016
Body: Condition:   Chronic Granulomatous Disease
Interventions:   Drug: Busulfan;   Biological: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Cyclosporine;   Procedure: Stem Cell Infusion
Sponsors:   Baylor College of Medicine;   Texas Children's Hospital
Active, not recruiting - verified July 2017
Body: Condition:   Lymphoma
Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: gemcitabine hydrochloride;   Drug: ifosfamide;   Drug: mechlorethamine hydrochloride;   Drug: melphalan;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vincristine sulfate;   Drug: vinorelbine tartrate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified May 2017
Body: Conditions:   Leukemia;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome
Interventions:   Drug: Clofarabine/Busulfan x 4;   Procedure: Peripheral blood stem cell transplant;   Radiation: Total Lymphoid Irradiation
Sponsors:   University of Michigan Cancer Center;   Genzyme, a Sanofi Company
Completed
Body: Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Active, not recruiting - verified August 2017
Body: Condition:   Graft Versus Host Disease
Intervention:   Drug: Interleukin-2
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Novartis
Active, not recruiting
Body: Condition:   Epidermolysis Bullosa
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: hematopoietic bone marrow transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated

Pages